News Hub | News Direct

All Industries


Article thumbnail News Release

Is Gamification The Future Of Advertising? Here’s How One Company Is Shaking Up The Industry

Overplay

By Faith Ashmore, Benzinga In the early 90s and even 2000s, ads were a key part of consuming media and advertising was, in a way, fun. Commercials were part of the popular culture monolith and it was clear that advertising budgets were spent with intention. Ask any 90s kid, and they can quote the most popular ads of the time, whether that is Tony the Tiger’s “They’re G-r-r-reat!” or Verizon’s (NYSE: VZ) “Can you hear me now?” Today, the landscape of ads has changed, and the overall feeling is not one of enjoyment but rather fatigue. Advertising seems to be missing its mark for the majority of viewers. While ads have always been looked at through the lens of doubt, only 4% of people in a recent study by Inc. Magazine believed they were trustworthy. Not to mention, people feel overwhelmed by the sheer volume of ads they are exposed to on a daily basis, which makes them more likely to tune them out. Additionally, the cultural significance of advertising has diminished due to the increasing amount of ads on the internet, and most ads are not viewed as entertaining or effective at selling products. There has also been recent discourse that criticizes the rise of "woke-wash" advertising or makes false claims about social or environmental responsibility just for profit. “It’s harder to reach audiences, the cost of marketing is going up, the number of channels has exponentially proliferated and the cost to cover all of those channels has proliferated,” Jay Pattisall, the lead author of a recent advertising report, shared in an interview. “It’s a continual pressure for marketers – we’re no longer just creating advertising campaigns three or four times a year and running them across a few networks and print.” What Does The Future Of Successful Advertising Look Like? In a world where everyone seems to despise ads, gamification could be the next frontier for advertising, with 2 out of 3 Americans spending an hour on gaming every day. In this landscape, Overplay emerges as a solution that aims to disrupt the status quo. Overplay leverages the power of gamification and introduces a new approach to advertising that transforms traditional ads into interactive games. By turning ads into engaging experiences, Overplay seeks to capture users' attention and boost their active participation. Overplay's innovative platform empowers creators to effortlessly infuse their videos with interactive elements, removing the need for coding skills and technical expertise. This democratization of interactive content creation opens up a world of possibilities for creators, allowing them to tap into the immense popularity of gaming culture quickly and easily. The result is a more immersive and enjoyable ad experience that stands out amidst the noise of traditional advertising. Not only does Overplay benefit creators, but it also offers value to brands. By harnessing the power of playable game ads, brands can connect with their target audience in a highly interactive and memorable way. Plus, playable ads have been shown to achieve a staggering 7x higher conversion rate compared to other ad formats, making them a powerful tool for driving results. With Overplay, brands can create these effective playable game ads at a fraction of the cost and time traditionally required. The allure of Overplay is undeniable, with hundreds of thousands of app downloads and millions of games played. By recognizing that the current zeitgeist has shifted away from enjoying ads, Overplay has set out to transform the advertising landscape by making ads more enjoyable, interactive and effective through the power of gamification. Featured photo by Joshua Earle on Unsplash. Overplay is revolutionizing a $574 billion digital media landscape with the first frictionless platform for user-generated games.With Overplay, everyone can turn their videos into games and share them with the world — in minutes, for free, with no code. Overplay’s app can be used to quickly and easily make games from anything: funny moments with your friends, cat memes, cooking tutorials, extreme sports POVs, and more!Imagine the NBA creating playable highlights reels, movie studios releasing trailers that are games, and car companies making commercials where you virtually test drive their cars. Overplay’s app and licensable technology allows billions of creators, social media users, and brands to amplify audience engagement by making their content interactive.Overplay sits at the intersection of three massive markets: social media, video advertising, and casual gaming. We are merging everything that makes these markets successful into one revolutionary form of digital media that will be consumed and created by BILLIONs of potential Overplayers worldwideWith Overplay’s API, brands can apply a thin layer of gaming on top of videos already being streamed in advertisements. Because our technology is so simple and takes only a few minutes, Overplay cuts down on thousands of hours of production time and millions of dollars in costs for brands to leverage this highly engaging ad format. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Caroline Strzalka caroline@overplay.com Company Website https://overplay.com/

June 04, 2024 09:00 AM Eastern Daylight Time

Image
Article thumbnail News Release

Avenix Fzco Launches Litepips: AI-Powered Trading Technology for Gold Market on MetaTrader 4 Platform

Rev Up Marketers

Avenix Fzco, a prominent player in algorithmic forex trading, has announced the launch of Litepips, its latest AI-driven trading technology tailored for the XAUUSD (gold) market on the widely-utilized MetaTrader 4 platform. Litepips introduces a novel trading system aimed at providing traders with a sophisticated tool for conducting comprehensive analysis of market impulses and trends. By integrating technical and mathematical evaluations, the platform enables precise trading decisions with the goal of optimizing profits while minimizing risks. Its advanced algorithms dynamically respond to changing market conditions, providing traders with an adaptive advantage. Emphasizing safety and reliability, Litepips eschews high-risk trading strategies like grid or hedge trading. Instead, it incorporates stringent risk management protocols with strategic stop-loss and take-profit settings, ensuring traders can engage with increased confidence and security. A key highlight of Litepips is its economic model, offering accessibility through a one-time purchase. This distinguishes Litepips from subscription-based trading solutions, appealing to traders seeking to minimize ongoing costs and reflecting the company’s commitment to providing value and transparency. The introduction of Litepips is poised to set a new standard in forex trading, making sophisticated trading tools more accessible and economically viable for traders worldwide. About Litepips: Litepips by Avenix Fzco is a forex trading platform leveraging cutting-edge AI and machine learning technologies to optimize trading strategies, with a focus on the gold market. Litepips aims to provide traders with powerful, precise, and accessible trading solutions. About Avenix Fzco: Avenix Fzco is a leading provider of Forex trading solutions, specializing in the development of expert advisors and trading tools designed to empower traders to achieve greater precision and profitability. With a focus on innovation and user-friendly design, Avenix Fzco is dedicated to helping traders succeed in the dynamic world of Forex trading. Contact Details Avenix Fzco Robert Swanton support@litepips.com Company Website https://litepips.com/

June 04, 2024 08:54 AM Eastern Daylight Time

Image
Article thumbnail News Release

Bitcoin (BTC) Stability Boosted By Massive ETF Inflows, Rebel Satoshi is on a dream presale run

Blockchain Digest

In the constantly changing world of cryptocurrency, periods of stability are really sought after, especially for Bitcoin (BTC). Right now, Bitcoin is seeing a boost in investor trust, thanks to big investments in spot BTC exchange-traded funds (ETFs) and favorable trading situations. At the same time, Rebel Satoshi Arcade (RECQ), a crypto project led by its community, is making great progress in its presale stage, catching the eye of both investors and fans. Massive ETF Inflows Boost Bitcoin Stability Bitcoin's recent stability can be credited to the huge influx of investments into spot BTC ETFs, signaling growing confidence among investors. According to Bitfinex researchers, Bitcoin has found solid support around the $60,000 level, thanks to consistently strong daily closures and significant withdrawals from crypto exchanges. Even with the massive outflows totaling $3.85 billion on May 15, Bitcoin's volatility remained low, and the cryptocurrency held its ground. What's particularly interesting is the spot Bitcoin ETF market in the US, which has seen net inflows for seven days in a row. This trend shows that investors are increasingly interested in BTC-related investment products, highlighting the growing appeal of Bitcoin as an asset class. Rebel Satoshi Arcade (RECQ) – Igniting The Wave Of Decentralization Picture this: in the bustling arena of cryptocurrency, Rebel Satoshi emerges as a beacon of hope, challenging the established presence of Bitcoin. It’s a rebellious project with the focus to transform the gaming and financial systems with complete decentralization. Do not think of Rebel Satoshi as another meme maniac, but a community-wide movement against the elites. With a unique dual-token system, featuring the Rebel Token (RBLZ) and the Requis Token (RECQ), it offers more than financial stakes – it stands for belonging and governance. If you hold this token, you are literally a decision maker in this project, while the other token serves a transactional purpose. The current presale has exceeded everyone's expectations with its remarkable success. Rebel Satoshi's innovative strategies and commitment to its community have generated immense interest and excitement. With ambitious goals outlined in its roadmap, such as reaching a $100 million market cap, Rebel Satoshi is poised for something substantial. And it's not mere speculation – comprehensive audits demonstrate the project's dedication to security and transparency, instilling confidence in potential investors. Rebel Satoshi isn't just about snagging investors; it's about making moves. Like, as this presale ramps up, it's drawing in investors who want to be a part of a bigger picture—a movement all about decentralization and making money stuff more fair for everyone. And, with each step it takes, Rebel Satoshi is cementing its spot as a big deal in the crypto scene. It's not just about throwing cash in; It's about having a shot at shaping a world where everybody gets a fair shake. Conclusion The combination of Bitcoin staying solid and all the hype around Rebel Satoshi’s presale is truly getting people excited about crypto. In this ever-changing world, projects like Rebel Satoshi offer a golden chance to be part of a community-driven push for a more inclusive financial future. Whether you’re a pro investor or just dipping your toes into crypto, now's the perfect time to check out Rebel Satoshi Arcade (RECQ) and dive into the vibe of innovation and empowerment. For the latest updates and more information, be sure to visit the official Rebel Satoshi Website or contact Rebel Red via Telegram. Contact Details Rebel Satoshi marketing@rebelsatoshi.com

June 04, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

DPH BIOLOGICALS DELIVERS NEXT GENERATION BIOLOGICALS WITH EXPANDED PORTFOLIO BUILT ON NOVEL TECHNOLOGY PLATFORM

DPH Biologicals

DPH Biologicals, a leading developer and supplier of agricultural biologicals, announced its new Prime platform that uses a patented production process for Bacillus spp., a leading plant growth rhizobacterium, to accelerate the germination of bacteria spores, supporting overall plant development while providing crops with more consistent resilience against heat, drought, and alkaline and saline soil conditions. “Historically biologicals have been dinged for inconsistent performance when used in a variety of environmental conditions. By utilizing a unique manufacturing process, we’ve enabled Bacillus spores to germinate faster resulting in more consistent performance especially in stressful conditions. Ultimately, Prime gives channel partners and growers more confidence in biologicals and allows them to differentiate from the plethora of microbial-based products on the market,” said Mick Messman, DPH Bio President and CEO. Kept in a dry, dormant state to germinate quicker, Prime spores colonize the root zone faster, capturing nitrogen while solubilizing potassium and phosphorus for more effective nutrient uptake. In a lab trial, Prime enabled more than 70% of Bacillus spores to germinate at temperatures as high as 98.6 degrees Fahrenheit, while those without Prime germinated less than 10% after 50 minutes. Additionally, nearly all spores with Prime germinated in high salt environments, while those that were not treated with Prime did not germinate. With exclusive rights, DPH Bio is the first to offer Prime-based products and has recently integrated Prime into several existing biofertilizers in its TerraTrove™ product line, including Envelix Prime available this fall and Essential™ Prime PAK available for the 2025 crop season. “We are excited to see results coming through our science-based approach to support our channel partners and growers. Powered by Prime, the next generation of biologicals delivers higher quality sustainable options that consistently work," said Messman. For more information about DPH Bio’s technology platforms – RegenAphex™ and Prime, as well as DPH Bio’s expanded product portfolio, visit www.dphbio.com. About DPH Biologicals DPH Biologicals, LLC attracts, develops and scales technologies improving broad market access and simplifying the grower experience with biologicals. Based on investments in scientific research, field testing, partner relationships and product development, and leadership-owned since 2024, DPH Bio yields success through science and relationships, standing at the leading edge of clarity, trust and proven, profitable solutions for agricultural biologicals. For more information, visit www.dphbio.com Contact Details AgTech PR for DPH Bio Georgie Smith georgie@agtechpr.com Company Website http://www.dphbio.com

June 04, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

PRCG | Sports Welcomes Renowned Sports Television Commentator Bob Costas to the “Crisis Communications in Sports” Podcast

PRCG I Sports

Legendary sports broadcaster Bob Costas joined the “Crisis Communications in Sports” podcast for a special edition that examined the scores of new challenges that have arisen in the sports world as a result of legalized sports betting. Hosts Jim Rocco and Chris Bruce asked the Sports Broadcasting Hall-of-Famer to share his insight on the ways he sees sports betting affecting the games we love to watch. “You can’t ignore the gigantic infusion of revenue that legalized gambling has meant to every league and every sports entity,” Costas said. “The very leagues that used to say that legalized gambling would be the death of sports as we know it, not only now accept it, but they embrace it and encourage it.” A 2018 Supreme Court ruling has led to legalized sports betting in 38 states and counting. That, coupled with smartphone technology, has made sports betting more convenient for fans than it has ever been at any point in history. This new normal presents unprecedented challenges for leagues, commissioners, coaches, officials, the athletes themselves, and of course, fans. “All the leagues, all they have to sell is the integrity of the competition,” Costas added. “If [sports betting] affects the outcome, or the perception of the outcome, that’s going to be a problem. You can see the commissioners getting together with the various betting sites and saying, let’s see if we can pull back on the aspects of this that are most problematic.” Over the course of his illustrious sports broadcasting career, Bob Costas has served as a play-by-play voice and studio host for Major League Baseball, the NFL, the NBA and was the prime-time host of 12 Olympic Games. He has won 29 Emmy Awards and is the only person in television history to have won Emmys for sports, news and entertainment. Costas was a 2018 inductee into the Sports Broadcasting Hall of Fame. Click here to listen to the full interview with Bob Costas on PRCG | Sports ’ “Crisis Communications in Sports” podcast. You can also follow us on Twitter @SportsComms_Pod, LinkedIn, or subscribe to our YouTube Channel. Also available on the News Direct Podcast Channel. Contact Details PRCG I Sports Jim Rocco +1 212-683-8100 jrocco@prcg.com PRCG I Sports Chris Bruce cbruce@prcg.com Company Website https://prcgsports.com/crisis-communications-in-sports/

June 04, 2024 08:30 AM Eastern Daylight Time

Image
Article thumbnail News Release

BNB Loses Market Interest, Solana and 100x Altcoin Raboo Steal the Spotlight

Total Media

The cryptocurrency market has experienced a series of bullish and bearish trends from a couple of major coins. With Solana demonstrating a massive recovery trajectory and BNB price moving sluggish, investors seem to be losing interest in BNB and pivoting to the newly created socialFi meme coin. Raboo is a brand-new SocialFi coin created with a combination of top-notch technology and a splash of amazing meme-hunting skills. This coin has stolen the spotlight as it is predicted to surge up to 233% in 2024. Raboo, currently in Stage 4 of its presale phase, and raking in over $1.6million so far, it’s projected by analysts to surge up 100x on launch day. In this article, we will talk more about all you need to know regarding the progress of this coin. BNB: Massive Decline in Market Price of Binance Coin Recently, the value of BNB had experienced a downward trend of about eight percent in comparison with the dollar value. This shows clearly that the token isn't going to bring in big ROI, causing investors to lose interest in the market coin. BNB has had a bullish short-term trend, rising fourteen percent during the last couple of months, analysts warn of BNB as it is approaching its resistance of $645.02. BNB is Currently trading at $621.05 with a trading volume of approximately $2.8 billion, and YTD value of only 100%. A Crypto analyst recently described the Binance Coin as having a bullish past, with a bearish future. Due to its recent performance, investors are now seeking other alternatives to dive into, with Raboo’s presale coin showing potentials of up to 100x its market value. Solana is predicted to surge by 10% in The Crypto Market The debut of meme-coins on the Solana blockchain has been met with excitement from investors. Using the unrestricted nature of blockchain technology, Solana is an open-source project with a huge operation that provides DeFi solutions. Solana Enthusiast projects that there is a high chance it will experience a bullish trend of up to 10% in the next couple of days. This is due to the increase in its overall trading volume and market cap. In the last 24 hours, Solana has had a trading volume of approximately $2.1 billion and a market price of $75.5bn. Raboo’s Bright Future of Up to 100x is Still Bringing in Investors Raboo is predicted to place among the top AI-themed meme coins in 2024, and it definitely has people talking. The price of the presale token is estimated to go up to 233%, following its starting price of $0.003 Currently in Stage 4 with a price of $0.0048.. In a market where investors are shifting toward meme coins, Raboo is a top-tier native token that has the potential to surge by 10,000% upon its listing on a major exchange platform. Raboo offer holders the opportunity to experience the combination of MemeFi, blockchain, and SocialFi. Enthusiasts get to benefit from the special social-fi model and earn more tokens by participating in weekly, monthly, and quarterly competitions. The new meme coin is driving the $62 billion meme market and without a doubt one of the best altcoin to invest in. Conclusion In the cryptocurrency space, not only Solana but also Binance Coin have experienced big hits. With the increase in solana trading volume and market cap, it’s expected to experience a 10% surge in the couple of days. Meanwhile, Raboo is stealing the spotlight following its prediction of reaching up to 100x its current price, investors are now finding their way to this AI-powered meme coin. You can participate in the Raboo presale here. Telegram: https://t.me/RabootokenPortal Twitter: https://twitter.com/Raboo_Official Contact Details Total Media Solutions media@Totalsolutionspr.io

June 04, 2024 08:24 AM Eastern Daylight Time

Image
Article thumbnail News Release

Novus Reports Q1 Results And Key Success Factors Following DEA Rescheduling

Novus Acquisition & Development Corp

Miami, Florida - ( ThriveNewsWire ) - Novus Acquisition & Development Corp d/b/a Novus Cannabis MedPlan (OTC Markets: ( NDEV ) is a leading national supplemental health insurance carrier and pioneer in offering cannabis in health plans for recreational and medicinal users. It released its update on its Q1 2024 results, Rx Dispensing Platform, and Key Elements that fuel its success after the Drug Enforcement Agency (DEA) announced that cannabis will be rescheduled. Novus Cannabis MedPlan (Novus) has been integrating cannabis into health plans since 2015. With a network of over 1,200 agents, brokers, and dispensaries, Novus aims to make cannabis-based treatments more affordable and accessible through insurance plans, benefitting a wider range of consumers. Here are three key highlights that contribute to Novus' success. 1) Financial Snapshot: The company utilizes a receivable-based business model with minimal overhead and no convertible debt, demonstrating consistent organic growth year over year. No Dilution: No common stock has been issued after June 15, 2021. No Sales of Insider Shares: For close to 3 years Gross Revenue Increase: During this reporting period, Gross Revenue increased by 6.8% compared to March 31, 2024 and 2023, respectively, Net Revenue Increase: During this reporting period, EBITDA increased by 19.47% compared to March 31, 2024, and 2023. Profit Margin: During the reporting period, the company experienced a gradual increase in gross profit margins, with margins of 43.14% in 2023 and 45.2% in 2024 Cash and Cash Equivalents: There was an increase of 1.8% compared to the financial reporting periods on March 31, 2024, and December 31, 2023. This is in contrast to the higher increase of 6.84% in the period from March 31, 2023, to 2024. Debt Transparency: Frank Labrozzi, the CEO, is owed $158,061. He has no plans to exercise the call provision, and this debt instrument has no equity conversion provision. Leak Out Vendor Shares: All vendors who received treasury-issued stock must gradually sell their shares. The selling amount is determined based on 15% of the average daily trading volume over the past 30 days. 2) Introducing the Rx Dispensing Platform Novus is strategically positioning its cannabis health plans to become a prominent player in mainstream healthcare insurance by acquiring an Rx Dispensing Platform tech stack. Frank Labrozzi, CEO of Novus, stated, "This advancement will significantly impact cannabis in health plans. By promoting collaboration between brands and dispensaries, we aim to empower policyholders with more choices, enabling them to purchase the brands they prefer at any dispensary. Cannabis brands can use the platform to connect directly with dispensaries and showcase their products at no cost. This will improve product distribution efficiency, increase brand visibility, provide real-time inventory data, and facilitate product research for the policyholder. An added bonus to For Rec Users: This platform serves recreational users who prefer not to disclose personal information like their policyholder status to access plan benefits. Instead, users can discreetly order services for a small subscription or transaction fee. 3) Key Success Factors Midwest Expansion: Novus has partnered with Heya Wellness, a prominent cannabis company in Missouri, to offer MedPlans to 4.3 million potential policyholders in the Midwest. By leveraging Missouri's favorable reciprocity laws, Novus aims to maximize the benefits for our sales hub based in St. Louis. Health Carrier Alliances Integration with Traditional Healthcare: By treating cannabis as a traditional pharmaceutical product and including it in insurance plans, Novus could help normalize cannabis use for medical, recreational, and non-users. Now that there is federal approval, Novus bridges traditional healthcare and the cannabis industry, enhancing major healthcare carriers who have expressed interest in integrating Novus' cannabis-based prescription plans into their benefits packages, establishing a connection between the two industries. Compassionate Care Act (CCA): The CCAs, which the Supreme Court sanctions, typically focus on making medical marijuana accessible to workplace patients with specific conditions. Human Resources departments are revising workplace policies to allow employees to access medical marijuana through employer-sponsored health plans. Novus plans to cover some costs through tax-deductible health savings and health reimbursement accounts. Opioid Settlement Framework: The opioid settlement framework is a legal agreement aimed at resolving litigation against pharmaceutical companies and health carriers accused of contributing to the opioid crisis. It includes $50 billion for prevention, treatment, and recovery programs with the goal of mitigating the crisis' impact and preventing future misuse. Novus is playing a crucial role in reducing opioid use by offering states and private organizations alternative treatment options through our developed health plans that help patients transition from opioids to medical cannabis. Compliance with the Veteran’s Affairs (VA): Veterans are increasingly interested in utilizing cannabis for treatment—over 88% support medical cannabis programs. Novus has developed health plans following VA guidelines to integrate cannabis benefits for veterans. In closing: As Novus adjusts to the positive changes in federal cannabis regulation, we are prepared to utilize our niche approach to cannabis in health plans, which utilizes a receivables-based business model. This approach strategically enables us to organically invest in critical areas such as marketing, improving engagement with policyholders and providers, and establishing a reliable cash flow management system. This positions Novus as a significant player in the fast-evolving cannabis integrated into health insurance plans. Do your research on our company to understand our potential in shaping the future of healthcare. Visit our Investor Relations page to see for yourself. About Novus Further Research: Financial Filings: Click Here Quote: Click Here Website Click Here Investor's Page Click Here Video Of Investment Highlights: Click Here Novus Acquisition & Development Corp. (NDEV) operates through its subsidiary, WCIG Insurance Services, Inc., offering health insurance and related insurance solutions in states with legal medical marijuana programs. With a robust infrastructure covering various insurance lines, including health, life, and fixed annuities, Novus is a leading health insurance carrier, using two key indicators to gauge value and performance. The Benefit Monetization Ratio measures the annual total of monetized policies, offset by the operating cost ratio, a Balance Sheet line item derived from Net Asset Value and calculated to the Price Book Value. Novus' medical cannabis benefits package operates as an outside developer. It does not engage in any activities related to the cultivation, handling, transportation, growth, extraction, dispensing, sale, marketing, vending, delivery, supply, circulation, or trade of cannabis or any substances violating United States law or the Controlled Substances Act. The company adheres strictly to state and federal laws and has no intentions to violate them in the future. It is important to note that statements regarding specific products have not been evaluated by the United States Food and Drug Administration (FDA) and should not be interpreted as intended to diagnose, treat, cure, or prevent disease. The information provided in press releases and product labels is for informational purposes only and should not be considered a substitute for advice from qualified healthcare professionals. Novus respects the individual transactions involving cannabis, which are solely between state-licensed dispensaries and registered patients. However, it's worth noting that state laws may conflict with the federal Controlled Substances Act. The current administration has indicated that federal law enforcement agencies will not prioritize prosecuting those complying with state-designated laws concerning medical marijuana usage and distribution. Nevertheless, changes in government policies and consolidation could impact the provider network, and there is no assurance that future administrations will not alter this stance. While Novus does not engage in the harvest, distribution, or sale of cannabis or cannabis-related products, the company could be affected if there were any shifts in enforcement by federal or state governments concerning existing laws. Such changes could result in significant financial implications for Novus and other industry players. Forward-Looking Statements This release includes forward-looking statements, which are based on certain assumptions and reflect management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include general global economic conditions; general industry and market conditions and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, includes codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. Dilution, if any, would be for the purposes of management taking stock in lieu of cash salary. Novus disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Additionally, this press release that is not statements of historical fact may be considered to be forward-looking statements. Written words such as "may," "will," "expect," "believe," "anticipate," "estimate," "intends," "goal," "objective," "seek," "attempt," or variations of these or similar words, identify forward-looking statements. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. Investor Contact Information Investor Website 855-228-7355 Email: pr@getnovusnow.com Contact Details Novus Acquisition Frank Labrozzi +1 305-467-6699 frank@ndev.biz Company Website https://getnovusnow.com/

June 04, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

AGC Biologics Completes Copenhagen Campus Expansion, Doubling Single-use Mammalian Bioreactor Capacity at Site

AGC Biologics

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced at BIO International the completion of its new manufacturing building at the AGC Biologics Copenhagen campus. The completed work doubles the site’s single-use bioreactor capacity for mammalian services and allows it to produce 150 more batches of drug product each year. The expansion adds 19,000 m2 of space in an ultramodern building that houses a large manufacturing floor, expanded quality control and process development lab space, utilities to support all operations and prevent outages caused by natural disasters, and a fully dedicated warehouse to serve the entire AGC Biologics Copenhagen campus. The new AGC Biologics Copenhagen manufacturing building is already in production with its first customer, a phase II/III clinical product. AGC Biologics announced the planned expansion in November 2020, investing roughly $200 million into the work. One-of-a-kind single-use manufacturing offering The new manufacturing area offers 8 x 2,000 L single-use bioreactors with two seed trains, as well as two independent downstream suites – [CW1] more than doubling the existing capacity offered at this site for mammalian-based projects. AGC Biologics Copenhagen is now one of the only sites in the world with multiple single-use bioreactor systems of this magnitude capable of producing batches at high-levels of clinical and commercial production. Further, for developers needing to transfer in an existing process, AGC Biologics Copenhagen’s multiple single-use suites give the site greater flexibility to take on technical transfers and perform like-for-like process and knowledge activities for products entering the facility, eliminating lag time associated with onboarding a new CDMO. AGC Biologics has been a leader in single-use technology over the last decade, and it is one of the largest CDMO networks in the industry offering flexible and scalable single-use bioreactors systems. The news comes after AGC Biologics announced an end-to-end protein biologics drug product partnership with Dutch-based BioConnection in late May. The alliance provides a secure and full-service “gene-to-vial” offering for biopharma developers with drug substance development, manufacturing and aseptic fill and finish capabilities for drug products. “AGC Biologics Copenhagen site continues to be one of the most active in our network with all the necessary commercial approvals – FDA, EMA, HCA, PMDA, ANVISA etc. – and we are more than happy to offer the capacity and capabilities our current and future customers will look for with this completed expansion,” said Christoph Winterhalter, CBO, AGC Biologics. “The expansion, combined with our new drug product alliance, demonstrates AGC Biologics’ agility to meet all the needs developers may have, from pre-clinical through commercial.” AGC Biologics’ Copenhagen site core teams of scientists have more than 25 years of expertise in biopharmaceutical development and manufacturing, including seven commercial products brought to market. The site offers pre-clinical through commercial production for protein biologics services using mammalian and microbial systems. It has a gold EcoVadis Sustainability Rating for its environmental, health and sustainability practices. “I am extremely proud of the work and collaboration of everyone at our site over the last several years, it is truly remarkable to see what we can accomplish by working together. We are eager to offer more of the important capabilities the industry is looking for to support patients in need,” said Andrea C. Porchia, General Manager, AGC Biologics Copenhagen. To learn more about AGC Biologics Copenhagen, visit www.agcbio.com/facilities/copenhagen. For more information about AGC Biologics’ global CDMO services go to www.agcbio.com. About AGC Biologics: AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan. We currently employ more than 2,500 Team Members worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is a part of AGC Inc.’s Life Science Company. The Life Science company runs more than 10 global facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com. Contact Details Nick McDonald +1 425-419-3555 nmcdonald@agcbio.com Company Website https://www.agcbio.com/

June 04, 2024 12:00 AM Pacific Daylight Time

Article thumbnail News Release

Mphasis and Classiq Partner to Drive Quantum Innovation

Classiq Technologies

Mphasis, (BSE: 526299; NSE: MPHASIS), an Information Technology (IT) solutions provider specializing in cloud and cognitive services, today announced its strategic partnership with Classiq, a leading quantum software company to demonstrate and commercialize industry solutions powered by Quantum. The strategic partnership aims to accelerate the adoption of quantum solutions for enterprises by integrating them into its operations. The collaboration is committed to fostering innovation and redefining technological boundaries and paving the way for a quantum-powered future. Classiq leads in quantum computing software and has developed a platform for faster and more efficient quantum algorithm design. Mphasis will focus on building industry solutions in sectors such as BFSI, Lifesciences, Healthcare, Supply Chain & Logistics, Chemistry, utilizing these advanced algorithms. By leveraging Classiq’s quantum platform, Mphasis will develop industry-specific intellectual properties (IPs) and will also jointly market and implement customer IPs, execute customer projects, and provide support for the commercialization of Classiq’s platform and IPs. Additionally, Mphasis’ Quantum Initiative, launched in 2020 within the Applied R&D division, NEXT Labs, aims to facilitate our client's transition to the quantum era. The adoption model comprises awareness-building, assessment, and consulting workshops, as well as the development and implementation of quantum solutions in key domains such as optimization, artificial intelligence, simulation, and cybersecurity. Within the realm of quantum computing, the company’s priorities include applied research, the creation of industry-specific solutions and intellectual properties, thought leadership dissemination, building robust partnerships, and leveraging a design thinking approach to drive adoption. “We are thrilled to announce our collaboration with Classiq and leveraging their expertise to unlock the vast potential of quantum computing. This partnership enables us to combine our industry knowledge with cutting-edge quantum technology, to innovative solutions tailored to our clients' needs. Together we hope to lead the way in initiating and implementing state-of-the-art quantum solutions that redefine the boundaries of our field," said Srikumar Ramanathan, Chief Solutions Officer, Mphasis. "Classiq is proud to be partnering with Mphasis to support scalable enterprise quantum computing software development. Together we combine depth of industry domain knowledge and quantum expertise with the technology needed to implement sophisticated optimized quantum computing programs for our clients," said Nir Minerbi, CEO and Co-Founder, Classiq Technologies. By synergizing Mphasis' domain expertise with Classiq's quantum computing acumen, the collaboration is poised to unlock newer possibilities and redefine industry benchmarks. Quantum computing's ability to tackle previously unsolvable problems opens doors for entirely new discoveries and innovations. National Institute of Standards and Technology’s report states that quantum computing could lead to breakthroughs in areas like materials science, drug discovery, and financial modelling. McKinsey & Company estimates a $106B potential quantum technology market size by 2040. The alliance between Mphasis and Classiq represents a fusion of expertise and innovation, with Classiq's cutting-edge quantum development platform complemented by Mphasis' extensive industry knowledge. Together, the companies aim to pioneer groundbreaking quantum solutions that will reshape sectors primed for transformative change. Classiq’s platform enables both beginner and expert designers to rapidly generate, analyze, and execute quantum circuits. The collaboration reflects the shared dedication of Mphasis and Classiq, showcasing a commitment to pioneering quantum computing applications across diverse industry sectors. Apart from this, in June 2021, Mphasis along with the Government of Alberta, and the University of Calgary signed an MoU to announce the launch of the world-leading Quantum City - Canada. The strategic partnerships were to accelerate talent development and the development of a quantum computing ecosystem in Calgary, driving R&D in the technology sector. In June 2022, Mphasis deepened its commitment to Canada by announcing a delivery center in Calgary, opening the center in Alberta for business. The Mphasis business ecosystem was positioned to reinforce the region's reputation as a leading hub for digital transformation, AI, quantum computing, and more, and contribute to Canada's growing digital sector. About Mphasis Mphasis’ purpose is to be the “Driver in Driverless Car” for Global Enterprises by applying next-generation design, architecture, and engineering services, to deliver scalable and sustainable software and technology solutions. Customer centricity is foundational to Mphasis, and is reflected in the Mphasis’ Front2Back ™ Transformation approach. Front2Back™ uses the exponential power of cloud and cognitive to provide hyper-personalized (C= X2C2TM =1) digital experience to clients and their end customers. Mphasis’ Service Transformation approach helps ‘shrink the core’ through the application of digital technologies across legacy environments within an enterprise, enabling businesses to stay ahead in a changing world. Mphasis’ core reference architectures and tools, speed and innovation with domain expertise and specialization, combined with an integrated sustainability and purpose-led approach across its operations and solutions are key to building strong relationships with marquee clients. Click here to know more. ( BSE: 526299; NSE: MPHASIS ) About Classiq Classiq Technologies, the leading quantum software company, provides an all-encompassing software platform (IDE, compiler and OS) with a single point of entry into quantum computing, from algorithm design to execution. Tailored to all levels of developer proficiency, Classiq aims to democratize access to quantum computing with software that equips customers to take full advantage of the quantum computing revolution. A low-code development environment that automates quantum programming ensures that a broader range of talents, including those with backgrounds in AI, ML and linear algebra, can harness quantum computing without requiring deep, specialized knowledge of how to program quantum computer hardware. Classiq also works closely with advanced computation hardware providers providing software for use with quantum computers, HPC and quantum simulators. Backed by powerful investors such as HPE, HSBC, Samsung, Intesa Sanpaolo and NTT, Classiq’s world-class team of scientists and engineers has distilled decades of quantum expertise into its groundbreaking software development platform. Follow Classiq on LinkedIn, X (formerly Twitter) or YouTube, join the Slack community, or try the Classiq platform. Contact Details Rainier Communications Michelle Allard McMahon +1 781-718-3248 classiqPR@rainierco.com Mphasis Corporate Communications Deepa Nagaraj +1 646-424-5160 deepa.nagaraj@mphasis.com Mphasis Corporate Communications Sumana Bhat +91 99029 80980 sumana.bhat@mphasis.com Company Website http://www.classiq.io/

June 04, 2024 02:04 AM Eastern Daylight Time

1 ... 192193194195196 ... 3788